Clearstead Trust’s Genmab GMAB Stock Holding History

Clearstead Trust’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-199	Closed	-$6.1K	–	1219
2025 Q3	$6.1K	Hold	199	–	–	﹤0.01%	718
2025 Q2	$4.11K	Buy	+199	New	+$4.08K	﹤0.01%	795

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Trust's GMAB Position: Q4 2025 in Review

Clearstead Trust sold out of Genmab (GMAB) in Q4 2025, closing a stake of 199 shares — an estimated $6.1K sold.

Clearstead Trust first reported a position in GMAB in Q2 2025 and held it in 2 quarters. The position peaked at $6.1K in Q3 2025. 293 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

Clearstead Trust reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
Clearstead Trust sold 199 Genmab shares in Q4 2025, an estimated $6.1K.
Clearstead Trust first reported a position in Genmab in Q2 2025 and held it in 2 quarters.
Clearstead Trust's Genmab position peaked at $6.1K in Q3 2025.
293 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Clearstead Trust's 13F filing for Q4 2025, filed 9 Feb 2026.